Differences in outcome of the interaction between Cryptococcus neoformans glucuronoxylomannan and human monocytes and neutrophils

被引:33
作者
Monari, C
Retini, C
Casadevall, A
Netski, D
Bistoni, F
Kozel, TR
Vecchiarelli, A
机构
[1] Univ Perugia, Dept Expt Med & Biochem Sci, Microbiol Sect, I-06122 Perugia, Italy
[2] Albert Einstein Coll Med, Dept Med, Div Infect Dis, New York, NY USA
[3] Univ Nevada, Dept Microbiol & Immunol, Reno, NV USA
关键词
C; neoformans; GXM; neutrophil; monocyte; capsular polysaccharide;
D O I
10.1002/eji.200323388
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Disseminated infections by the opportunistic yeast Cryptococcus neoformans are characterized by accumulation in tissues of glucuronoxylomannan (GXM), the major component of the capsular polysaccharide. We investigated binding, uptake, and disposal of GXM by peripheral blood neutrophils and monocytes, and the effect of GXM uptake on phagocytic cell function. GXM was efficiently bound and internalized by both types of phagocytic cells, with maximal loading at 50 mug/ml, a GXM concentration found in serum and cerebrospinal fluid of some cryptococcosis patients. However, substantial differences were noted in the kinetics for uptake by macrophages and neutrophils. Whereas neutrophils rapidly ingested limited amounts of GXM and then expelled or degraded it after 1 h of incubation, macrophages demonstrated continuous intracellular accumulation for up to 1 week of incubation. Accumulation of GXM by neutrophils was accompanied by reduced anticryptococcal activity, suggesting one more mechanism for virulence enhancement by the major capsular component of C. neoformans.
引用
收藏
页码:1041 / 1051
页数:11
相关论文
共 44 条
[1]  
[Anonymous], 1973, Carbohydrate Research
[2]  
Antal-Szalmás P, 2000, CYTOMETRY, V41, P279, DOI 10.1002/1097-0320(20001201)41:4<279::AID-CYTO6>3.0.CO
[3]  
2-B
[4]  
BENNETT JE, 1964, T ASSOC AM PHYSICIAN, V77, P145
[5]   CRYPTOCOCCUS NEOFORMANS .2. PHAGOCYTOSIS BY HUMAN LEUKOCYTES [J].
BULMER, GS ;
SANS, MD .
JOURNAL OF BACTERIOLOGY, 1967, 94 (05) :1480-+
[6]   CRYPTOCOCCUS NEOFORMANS .I. NONENCAPSULATED MUTANTS [J].
BULMER, GS ;
SANS, MD ;
GUNN, CM .
JOURNAL OF BACTERIOLOGY, 1967, 94 (05) :1475-&
[7]   CRYPTOCOCCUS NEOFORMANS .3. INHIBITION OF PHAGOCYTOSIS [J].
BULMER, GS ;
SANS, MD .
JOURNAL OF BACTERIOLOGY, 1968, 95 (01) :5-&
[8]   STRUCTURE AND ANTIGENIC ACTIVITY OF THE CAPSULAR POLYSACCHARIDE OF CRYPTOCOCCUS-NEOFORMANS SEROTYPE-A [J].
CHERNIAK, R ;
REISS, E ;
SLODKI, ME ;
PLATTNER, RD ;
BLUMER, SO .
MOLECULAR IMMUNOLOGY, 1980, 17 (08) :1025-1032
[9]   A GALACTOXYLOMANNAN ANTIGEN OF CRYPTOCOCCUS-NEOFORMANS SEROTYPE-A [J].
CHERNIAK, R ;
REISS, E ;
TURNER, SH .
CARBOHYDRATE RESEARCH, 1982, 103 (02) :239-250
[10]   FACTORS INFLUENCING KILLING OF CRYPTOCOCCUS-NEOFORMANS BY HUMAN LEUKOCYTES IN-VITRO [J].
DIAMOND, RD ;
ROOT, RK ;
BENNETT, JE .
JOURNAL OF INFECTIOUS DISEASES, 1972, 125 (04) :367-&